Weeks after the Food and Drug Administration said opioid painkiller Opana ER should be removed from the market amid concerns about the potential for abuse, Endo Pharmaceuticals has agreed to pull the drug, which has been linked to serious outbreaks of HIV and hepatitis C. [More]
